How to Evaluate a DTC Pharma Landing Experience
A joint media and content checklist for DTC pharma landing pages covering message match, speed, risk information, accessibility, and next steps.
The short answer
DTC pharma media is often judged by what happens after the click. If the landing page is slow, confusing, or disconnected from the ad, good media looks bad. But landing pages are usually owned by a different team than media, and problems fall between them. A shared checklist helps both teams find the real issue.
The evaluation checklist
1. Message match
- Does the headline reflect the ad's main message?
- If the ad targeted a specific audience or symptom, does the page speak to it?
- Is the person clear on why they arrived?
2. Speed and stability
- How long does the page take to load on a mid-range phone on a mobile network?
- Does the layout shift as elements load?
- Are heavy scripts or tags slowing the page? Too many tracking tags can hurt both speed and privacy compliance.
3. Risk information and fair balance
- Is required safety information present and readable?
- Is it presented in a way that is consistent with the page's benefit claims?
- The FDA's guidance on presenting risk information is the reference for your review team.
4. Accessibility
- Does the page meet WCAG standards?
- Are videos captioned?
- Can someone complete key actions using a keyboard or screen reader?
5. Clear next step
- Is there one obvious primary action?
- Does it match what the person most likely wants: learn more, talk to a doctor, check cost, or find support?
- See connecting DTC media with patient support.
6. Privacy and tracking
- Which tags fire, and what data do they send?
- Are tracking practices consistent with the brand's privacy policy and HHS guidance on online tracking technologies where it applies?
Separate media problems from page problems
Look at landing page metrics by media source. If one partner's traffic bounces far more than others, the problem is likely traffic quality. If all traffic bounces at similar rates, the page is likely the issue.
| Pattern | Likely cause |
|---|---|
| High bounce from one partner only | Traffic quality or audience mismatch |
| High bounce across all sources | Page speed, message match, or design |
| Good engagement, few conversions | Unclear next step or form friction |
| Big gap between clicks and page visits | Slow load or tracking loss |
See the funnel diagnostic for a fuller breakdown.
Test changes carefully
Page changes in pharma go through review, so test the changes most likely to matter: message match and next-step clarity usually beat color or layout tweaks. Where possible, split traffic so you can compare versions over the same period.
Practical takeaway
Run the six-part checklist jointly with the web and media teams before launch and again after the first two weeks. Record which team owns each fix.
Sources
- FDA, Presenting Risk Information in Prescription Drug and Medical Device Promotion
- W3C, Web Content Accessibility Guidelines
- HHS, Use of Online Tracking Technologies by HIPAA Covered Entities
External guidance and platform documentation change. Links were current at publication; check them again before relying on them for a decision.
Editorial note. Analysis and frameworks are the author's own and do not represent Acxiom or any current or former employer, client, or named platform. Examples labeled hypothetical or illustrative are not results from real campaigns. Nothing here is legal, regulatory, or medical advice.
New pharma programmatic breakdowns, occasionally
One email when I publish something worth reading. Benchmarks, measurement teardowns, and case studies with the caveats attached. No cadence promises, no reselling your address.
Unsubscribe any time. See the privacy policy.
Working through this decision on a real plan?
I work on health and pharma data, identity, and activation, after five years running HCP and DTC programmatic agency-side. Happy to talk through how this applies to your situation.